CWI1-2

CWI1-2 is an IGF2BP2 inhibitor that binds IGF2BP2 and inhibits its interaction with m6A-modified target transcripts, induces apoptosis and differentiation, and shows promising anti-leukemic effects[1].

Signaling Pathways >> Apoptosis >> Apoptosis

Research Areas >> Cancer

CWI1-2 (0-1 μM, 24 h) 具有良好的抗白血病功效[1]。 Apoptosis Analysis[1] Cell Line: MonoMac6, MOLM13 Concentration: 0-1 μM Incubation Time: 24 h Result: Induced significant cell differentiation and apoptosis in a concentration-dependent manner in IGF2BP2-high cells but not in IGF2BP2-low cells. Reduced Gln uptake and impaired mitochondrial function, resulting in reduced ATP production in AML cells. Significantly inhibited the colony-forming ability of MA9-induced leukemic mouse blasts and greatly impairs the self-renewal of LSC/LIC.

CWI1-2（5 mg/kg，i.v.，每日一次，7-10天）可显着延缓 BMT 受体 B6.SJL（CD45.1）小鼠白血病的发生和存活时间，体重无明显影响 [1]。

[1]. Hengyou Weng, et al. The m6A reader IGF2BP2 regulates glutamine metabolism and represents a therapeutic target in acute myeloid leukemia. Cancer Cell. 2022 Dec 12;40(12):1566-1582.e10.